CAR-based cellular therapies for autoimmune diseases: immune reset, clinical evidence, and translational boundaries.
Engineered immune cell therapies show early promise in severe autoimmune diseases, but researchers call for larger trials and long-term safety tracking before widespread use.
This structured narrative review (updated through July 2026) evaluates CAR-T and related cellular therapies across severe autoimmune indications including SLE, systemic sclerosis, rheumatoid arthritis, autoimmune cytopenias, and neurologic disorders, extracting study-level data and handling overlapping cohorts explicitly. The review calls for disease-specific comparative trials, biomarker-guided platform selection, standardized immune-reconstitution endpoints, and long-term registries before CAR therapy expands beyond investigational programs in autoimmune disease.
What the study was
- Study design
- structured_narrative_review
- Population
- Patients with severe autoimmune diseases receiving CAR-based cellular therapy across published studies (review covers SLE, SSc, RA, autoimmune cytopenias, neurologic disorders)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplant Cell Ther
Why it surfaced
Timely synthesis (Transplant Cell Ther, July 2026 update) of rapidly evolving CAR-T evidence in autoimmune diseases, with critical operational definition of 'immune reset' and explicit framework for future trial design—directly relevant to translation from oncology to rheumatologic and neurologic indications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.